Copertina

PSA Density and Lesion Volume: Key Factors in Avoiding Unnecessary Biopsies for PI‐RADS 3 Lesions

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Ali Ayranci, Ufuk Caglar, Huseyin Burak Yazili, Feyzi Sinan Erdal, Akif Erbin, Omer Sarilar, Faruk Ozgor
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	The Prostate
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

The Effects of the Blood‐Based S2,3PSA% Test on Prostate Cancer Screening: A Novel Approach to Reduce the Need for MRI and Unnecessary Biopsies
di: Hikari Miura, et al.
Pubblicazione: (2025)

Individualized Precision Prostate Biopsy Strategy for Patients With PI‐RADS Score 2: A Retrospective Multicenter Study
di: Zhiyao Xu, et al.
Pubblicazione: (2025)

Diagnostic Performance of the Novel Biomarker S2,3PSA Density for Prostate Biopsy Optimization in Prostate Imaging Reporting and Data System 3–5 Lesions
di: Takanori Tokunaga, et al.
Pubblicazione: (2025)

The Role of Secondary Lesion Biopsy in Detecting Clinically Significant Prostate Cancer
di: Trevor C. Hunt, et al.
Pubblicazione: (2025)

Combining Prostate‐Specific Antigen Density With PI‐RADS to Improve the Detection of Clinically Significant Prostate Cancer at MRI/TRUS Fusion‐Targeted Re‐Biopsy
di: Yuto Ono, et al.
Pubblicazione: (2025)

Influence of 5‐Alpha Reductase Inhibitors on PI‐RADS Scores and Prostate Cancer Detection: A Systematic Review and Meta‐Analysis
di: Lian Qiong, et al.
Pubblicazione: (2025)

Serum levels of prostate specific antigen, free PSA, [−2]proPSA, fPSA/tPSA ratio, Prostate Health Index, and glycosylation patterns of free PSA in patients with benign prostatic hyperplasia pharmacotherapy
di: Michal Jirásko, et al.
Pubblicazione: (2024)

The predictive impact of hematological inflammatory markers in detecting prostate cancer in patients with PI‐RADS 3 lesions on multiparametric magnetic resonance imaging
di: Ridvan Kayar, et al.
Pubblicazione: (2024)

Serum Levels of Prostate Specific Antigen, Free PSA, [‐2]proPSA, fPSA/tPSA Ratio, Prostate Health Index, and Glycosylation Patterns of Free PSA in Patients With Benign Prostatic Hyperplasia Pharmacotherapy: Limitations and Future Directions
di: Yitong Weng, et al.
Pubblicazione: (2025)

Impact of PSA nadir, PSA response and time to PSA nadir on overall survival in real‐world setting of metastatic hormone‐sensitive prostate cancer patients
di: Mike Wenzel, et al.
Pubblicazione: (2024)

Microbial Differences in Prostate Lesions Between Black and White American Men
di: Shiv Verma, et al.
Pubblicazione: (2026)

Altered Glycosylation of PSA in Prostate Cancer Tissue
di: Hannu Koistinen, et al.
Pubblicazione: (2025)

Prostate Volume and PSA‐Density Estimation by Transabdominal Ultrasound: Prospective Evidence of Comparative Accuracy to MRI and Transrectal Ultrasound in Prostate Cancer Early Diagnostics
di: Liza M. Kurucz, et al.
Pubblicazione: (2025)

Current Status of Prostate Biopsy in Africa: Are We Ready for a Targeted Biopsy?
di: Ziba Ouima Justin Dieudonne, et al.
Pubblicazione: (2025)

Is Saturation Biopsy Still a Viable Alternative to Fusion Biopsy in the Era of Multiparametric MRI? A Comparative Analysis in Patients With Prior Negative Biopsy
di: Arda Taşkın Taşkıran, et al.
Pubblicazione: (2026)

The Role of Dynamic Contrast Enhanced Magnetic Resonance Imaging in Evaluating Prostate Adenocarcinoma: A Partially‐Blinded Retrospective Study of a Prostatectomy Patient Cohort With Whole Gland Histopathology Correlation and Application of PI‐RADS or TNM Staging
di: Sajeev Sridhar, et al.
Pubblicazione: (2024)

Beyond Baseline: Serial PSA Measurements and Risk Stratification for Prostate Cancer
di: Anwar E. Ahmed, et al.
Pubblicazione: (2025)

Optimizing Prostate Cancer Diagnostic Work‐Up Through Micro‐Ultrasound: Minimizing Unnecessary Procedures and Reducing Overdiagnoses
di: Edoardo Beatrici, et al.
Pubblicazione: (2025)

Propensity Score Matched Analysis of External Beam Radiotherapy With or Without Focal Boost to Intraprostatic Lesions in Prostate Cancer
di: Cem Onal, et al.
Pubblicazione: (2025)

Size and SUVmax define the contribution of nodal metastases to PSA in oligorecurrent prostate cancer
di: Fabian Falkenbach, et al.
Pubblicazione: (2024)

Outcomes of 10 years of PSA screening for prostate cancer in Norwegian men with Lynch syndrome
di: Eli Marie Grindedal, et al.
Pubblicazione: (2024)

A Multimarker Model for Prostate Cancer Risk Assessment: Improving Diagnostic Accuracy Beyond PSA
di: Penglu Yang, et al.
Pubblicazione: (2025)

Biopsy‐Free Radical Prostatectomy: An Innovative Investigational Approach
di: Changming Wang, et al.
Pubblicazione: (2025)

USPSTF Recommendation Against PSA Screening vs. Stage and Cancer‐Specific Mortality in Localized Prostate Cancer
di: Fabian Falkenbach, et al.
Pubblicazione: (2025)

LGALS3 cfDNA methylation in seminal fluid as a novel prostate cancer biomarker outperforming PSA
di: Irena Abramovic, et al.
Pubblicazione: (2024)

Association of Weight Loss and BMI on PSA Levels and Overall Survival in Veterans With Metastatic Castrate‐Resistant Prostate Cancer
di: Nicholas Fedele, et al.
Pubblicazione: (2025)

The role of different PI-RADS versions in prostate multiparametric magnetic resonance tomography assessment
di: Paulius Aliukonis
Pubblicazione: (2017)

Utility of the PROSTest, a Novel Blood‐Based Molecular Assay, Versus PSA for Prostate Cancer Stratification and Detection of Disease
di: Mark Kidd, et al.
Pubblicazione: (2025)

Comparative Evaluation of Detection Rates for Clinically Significant Prostate Cancer Using MRI‐Targeted Biopsy Alone Versus in Combination With Systematic Biopsies: Development of a Risk‐Stratification Scoring System
di: Toshifumi Takahashi, et al.
Pubblicazione: (2024)

Baseline Imaging Derived Factors of Response Following [225Ac]Ac‐J591 Therapy in Metastatic Castration‐Resistant Prostate Cancer: A Lesion Level Analysis
di: Judith Stangl‐Kremser, et al.
Pubblicazione: (2025)

Challenging the Evolving Nomenclature of Ultrasound‐Guided Transperineal Prostate Biopsy: A Call for Standardization
di: Pedro Ivo C. Ravizzini, et al.
Pubblicazione: (2026)

The Prognostic Significance of Radiographic Progression Without PSA Progression in Patients With Metastatic Hormone‐Sensitive Prostate Cancer Treated With First‐Line ARPI Therapy
di: Takeshi Tsutsumi, et al.
Pubblicazione: (2026)

Automatic MRI‐TRUS Fusion Technique for Transperineal Biopsy Guidance: From Preoperative Planning to Intraoperative Navigation
di: Lu Tang, et al.
Pubblicazione: (2024)

Reply – Letter to the Editor: Bimodal Imaging at MRI Fusion Prostate Biopsy Will Gain Further Importance in the Future
di: Fabian Falkenbach, et al.
Pubblicazione: (2025)

Letter to the Editor Regarding “Challenging the Evolving Nomenclature of Ultrasound‐Guided Transperineal Prostate Biopsy: A Call for Standardization”
di: Eriz Özden, et al.
Pubblicazione: (2026)

A west African ancestry‐associated SNP on 8q24 predicts a positive biopsy in African American men with suspected prostate cancer following PSA screening
di: Jian Gu, et al.
Pubblicazione: (2024)

Deep PSA response and extended time‐to‐nadir as robust predictors of survival in Asian patients with de novo metastatic hormone‐sensitive prostate cancer receiving upfront intensified treatment
di: Chris H.‐M. Wong, et al.
Pubblicazione: (2024)

Predictive Value of PSA Bounce Phenomenon after Stereotactic Body Radiation Therapy in a Large Population of Prostate Cancer Patients Treated By 1.5 T MR Guided Adaptive Technique
di: Andrea Romei, et al.
Pubblicazione: (2025)

Spatial Distribution of Prostate Cancer Missed by MRI‐Targeted Biopsy, Effect of a Perilesional Template, and Restaging in a Radical Prostatectomy Cohort
di: Ruth Himmelsbach, et al.
Pubblicazione: (2026)

Long‐Term Oncological Outcomes of Robot‐Assisted Radical Prostatectomy for Clinically Localized Grade Groups 4 and 5 Prostate Cancers Diagnosed on Prostate Biopsy
di: Victor Sandoval, et al.
Pubblicazione: (2025)